Anti-idiotypic MAb were raised in syngeneic mice against a mouse MAb recognizing GD3 ganglioside (MAb R24). Two anti-idiotypic MAb, designated BEC2 and BEC3, recognized distinct determinants on MAb R24 that mapped near or within the GD3-binding site. New Zealand white rabbits, which express GD3 on normal tissues, were immunized with either BEC2, BEC3, or control MAb FLOPC-21. All rabbits developed high and equivalent titers of antibodies against mouse immunoglobulins. Immunization with BEC2 and BEC3 induced rabbit antibodies expressing R24 idiotype as demonstrated by their ability to inhibit BEC2 binding to R24. Antibodies (IgG and IgM) reacting with GD3 developed in five of eight rabbits immunized with BEC2 but not in rabbits immunized with BEC3 or with control MAb. Serum antibodies against GD3 did not cross-react with other gangliosides. These results show that MAb BEC2 can mimic GD3 ganglioside and can induce antibodies against GD3 ganglioside despite expression ofGD3 on normal rabbit tissue. (J. Clin. Invest. 1991. 88:186-192.)
Introduction
Gangliosides are polymorphic glycolipids found on surface membranes of most cell types and, as a rule, are weakly immunogenic (I1-3). The major antigenic determinants ofgangliosides are carbohydrates which typically generate T cell-independent humoral immune responses. However, in certain circumstances, gangliosides can function as autoantigens: (a) antibodies against gangliosides have been detected in sera of patients with autoimmune diseases (4); (b) antibodies against the gangliosides GD2 and GM2 have been found in the sera of melanoma patients (5) , and human IgM MAb against gangliosides have been isolated from B cells of melanoma patients (6) (7) (8) ; (c) immunization with selected purified gangliosides has been shown to induce antibody responses in mice (1); and (d) immunization with GM2 and BCG adjuvant has induced IgM antibodies against GM2 in a majority ofpatients with metastatic melanoma (9) .
GD3 is a ganglioside abundantly expressed on most human melanoma cells (10) . GD3 has received attention as a possible target for active and passive immunotherapy of human melanoma and other neuroectoderm-derived tumors (2, (11) (12) (13) . In mice, which express little GD3 on normal tissues (1), antibodies against GD3 can readily be induced by immunization with purified GD3 plus adjuvant (1) . However, in humans and other mammalian species, GD3 is more abundantly expressed on selected normal tissues, including the central nervous system, adrenal medulla, and other tissues derived from the neuroectoderm (14, 15) . In these species, immunization with purified GD3 plus adjuvant does not generally induce antibodies against GD3 (1)-An alternative strategy for inducing antibodies against gangliosides involves the use of anti-idiotypic MAb (16) . This approach requires that a polypeptide Ig variable region can mimic a carbohydrate determinant, providing a surrogate immunogen. Anti-idiotypic MAb that mimic other carbohydrate antigens, such as bacterial LPS (17) (18) (19) and ,B2--'6 fructosan (20) , have been produced. In the LPS system, anti-idiotypic MAb can be superior to the original antigen in priming neonatal mice to respond (17) . We describe an anti-idiotypic MAb that mimics antigenic determinants on GD3 and induces antibody responses in a species (rabbits) that express GD3 on normal tissues.
Methods
Animals. Mice were purchased from Charles River Professional Services, Wilmington, MA and New Zealand White (NZW)' rabbits were from Hazelton Research Products (Denver, PA) or from Cocalico Biologics, Inc. (Reamstown, PA).
Materials. Cells were cultured in RPMI 1640 with 10% fetal bovine serum or 10% Serum Plus (Hazelton Research Products, Inc., Lenexa, KS). Media was supplemented with 2 mM glutamine, 1% nonessential amino acids, penicillin (100 U/ml), and streptomycin (100 U/ml).
GD3 was purified from bovine brain. Other purified gangliosides were purchased from Calbiochem-Behring Corp., La Jolla, CA. An MAb was considered to be inhibitory if the MAb IC50:R24 IC5o ratio was less than 10. To map binding sites, cross-blocking experiments were performed using anti-idiotypic MAb biotinylated using either biotin hydrazide (24) or N-hydroxysuccinimidobiotin (both from Sigma Chemical Co.). Nonbiotinylated, blocking anti-idiotypic MAb was added to 96-well plates coated with R24 (1 ug/well). After 1 h, biotinylated anti-idiotypic MAb was then added. Plates were washed after 1 h and wells were incubated with alkaline phosphatase-conjugated avidin for 15 min. Plates were developed as above.
The expression of R24 idiotype by rabbit antibodies was measured by inhibition assay in which various dilutions ofrabbit sera were preincubated with biotinylated BEC2 (0.38 gg/ml) and the mixture was added to 96-well plates coated with R24 (1 sg/well). After 1 h, wells were washed and bound BEC2 was detected by adding alkaline phosphatase-conjugated avidin and developed as above.
To measure anti-GD3 reactivity in the serum ofimmunized rabbits, purified GD3 was adsorbed to 96-well plates (100 ng/well). After blocking wells with 5% nonfat milk, test serum was diluted in PBS/ I% BSA/ 0.05% Tween 20 and added to wells for 1 h. Plates were washed and bound rabbit antibody was detected using alkaline phosphatase-conjugated goat antiserum specific for rabbit IgG (Sigma Chemical Co.).
Anti-GD3 serum titers were defined as the highest serum dilution yielding an absorbance reading greater than three standard deviations above the mean background reading. Rabbits were considered to have developed anti-GD3 antibodies if a fourfold or greater rise in titer above preimmune serum was observed in serum samples taken from at least two separate time points. 
Results
Anti-idiotypic MAb against R24. Syngeneic mice were immunized with MAb R24 (as described in Methods). Three mice demonstrating the highest titer serum reactivity against R24 F(ab')2 fragments were selected for fusions. 651 wells were screened from three separate fusions. Two hybridomas were identified and subcloned that produced MAb recognizing F(ab')2 fragments of R24. The hybridomas and the MAb produced by them were designated BEC2 (IgG2b) and BEC3 (IgG3).
The specificities of BEC2 and BEC3 were determined by inhibition assays using a panel of MAb (Table I) The determinants recognized by BEC2 and BEC3 were further defined by experiments that showed both BEC2 and BEC3 could cross-inhibit binding ofeach other to R24 (Fig. 1) rabbits (3) or humans (1); and (c) both rabbit (25) (26) (27) and human normal tissue (14, 15, 23) can express GD3 ganglioside. Immunostaining with MAb R24 confirmed that GD3 is expressed on normal rabbit tissues in a distribution similar to human tissues (Cordon-Cardo, C., P. B. Chapman, and A. N. Houghton, unpublished observations).
NZW rabbits were immunized with either BEC2, BEC3, or control MAb (FLOPC-2 1) . As expected, all rabbits developed high titer IgG against mouse Ig after a single inoculation with each ofthese mouse MAb. Peak anti-mouse Ig titers developed after a median of three (range, two to five) inoculations with a median peak titer of 1:656,000 (range, 1:121,000 to 1:2,000,000). There were no significant differences between the titers of anti-mouse Ig induced by each of the three mouse MAb, demonstrating that the three MAb were equally immunogenic.
Sera were assayed for IgG antibodies against GD3 ganglioside. Five of eight rabbits immunized with BEC2 developed IgG antibodies reacting with purified GD3 by ELISA, but no antibodies reacting with GD3 were induced in six rabbits immunized with either BEC3 or with FLOPC-2 1 (P = 0.028, Fisher's exact probability test). Fig. 3 illustrates the mean preimmunization and peak postimmunization IgG reactivity against GD3 for all animals immunized. Immunization with BEC2 induced IgG against GD3 with a mean peak titer of 1:160 (range, 1:80 to 1:640) (Fig. 3 A) . In contrast, after immunization with either BEC3 or FLOPC-2 1, no detectable reactivity against GD3 was induced in any rabbit (Fig. 3 , B and C).
We confirmed that the antibody response to GD3 was IgG class. First, the antibody response against purified GD3 could be detected using '251-protein A (see Fig. 5 Fig. 4 shows the typical time course of the IgG response against GD3 in a rabbit immunized with BEC2. IgG antibodies against GD3 were generated after the second, third, and fourth immunizations with BEC2. In some rabbits, titers appeared to decline after the fifth immunization. It should be noted that the last two immunizations were administered without adjuvant. However, IgG antibodies against GD3 could be detected as long as 107 d after the last immunization (data not shown), demonstrating that the anti-GD3 IgG response could be long lived. While sera with anti-GD3 reactivity could inhibit R24 binding to GD3, this effect was not specific. Sera from rabbits immunized with BEC3 or with FLOPC-21 could also inhibit R24 binding to GD3 suggesting that this effect was due to rabbit anti-mouse antibodies.
It is not uncommon for antibody responses against gangliosides to cross-react with carbohydrate determinants on distinct gangliosides (6) . For this reason, we were interested in analyzing the specificity of the anti-GD3 reactivity induced by BEC2. Immunoblot analysis of sera from selected rabbits immunized with BEC2 showed the presence ofboth IgM (Fig. 5 A) and IgG antibodies (Fig. 5 B) against GD3. These antibodies did not cross-react with the other gangliosides tested, including the ganglioside GM3, which differs from GD3 by the absence ofa single sialic acid moiety. Overall, these data demonstrate that, although immunization with BEC2 and BEC3 MAb induced high and equivalent titers of anti-mouse IgG, only immunization with BEC2 induced an IgG response against GD3.
Expression ofR24 idiotype by Ab3. In order to determine whether rabbit antibodies induced by BEC2 expressed an R24 LacCer, lactosylceramide.
idiotype, the ability of rabbit antisera to inhibit binding between BEC2 and R24 was tested (Fig. 6 ). All eight rabbits immunized with BEC2 developed antibodies that could inhibit BEC2 binding to R24. These inhibitory antibodies were induced even in the rabbits that did not develop anti-GD3 reactivity. Rabbits immunized with BEC3 also developed antibodies capable of inhibiting BEC2 binding to R24, but the titer of these antibodies was considerably lower. Immunization with FLOPC-21 did not induce antibodies capable of inhibiting BEC2-R24 binding, despite the fact that FLOPC-2 1 induced a comparable level of rabbit anti-mouse antibodies. These data show that immunization with BEC2, and to a lesser extent BEC3, induces antibodies in rabbits that express the R24 idiotype. In summary, these data show that BEC2 carries an internal image ofGD3 ganglioside, based on the finding that immunization ofNZW rabbits with BEC2 induced IgG responses against GD3 ganglioside. This anti-GD3 response occurred despite the expression of GD3 by normal rabbit tissues. It is interesting to note that none of the rabbits showed clinical or pathological evidence of adverse effects due to immunization with BEC2. Necropsy specimens of selected rabbits with IgG antibody response against GD3 after immunization with BEC2 showed no histologic evidence ofimmune cell infiltration or tissue destruction in organs that express GD3, such as brain, adrenal gland, liver, and small intestines.
Discussion
Jerne proposed that the immune system can be regulated through a network of antibody/anti-idiotype interactions (29) . One of the implications of this model is the existence of antiidiotypic antibodies that carry internal images of every recognizable determinant. Consistent with this model, anti-idiotypic MAb can be identified that carry the internal image of nonprotein determinants (17) (18) (19) (20) 30) . In tumor antigen systems, antiidiotypic MAb have usually been used to mimic protein antigens (16, 31, 32) although Viale and co-workers have described an anti-idiotypic MAb that carries the internal image of an undefined saccharide determinant expressed on tumor-associated glycolipids and glycoproteins (33) . We present data that the anti-idiotypic MAb BEC2 carries an internal image of the ganglioside GD3. Presumably BEC2 mimics a determinant that includes a terminal N-acetyl neuraminic acid because this moiety is critical for R24 binding to GD3 (34) . A B A number of investigators have shown that anti-idiotypic MAb can be used as surrogate antigens to induce immunity (16) . In infectious disease models, there is evidence that selected anti-idiotypic MAb can be better immunogens compared to the original antigen (17) . Previous work has shown that purified GD3 is a poor immunogen in species that express GD3 on normal tissues ( 1-3) , possibly due to a state ofrelative B cell tolerance to cell surface GD3. The experiments with BEC2 immunization demonstrate that B cells that can secrete antibodies against GD3 remain in the immune repertoire of the rabbit.
Titers of anti-GD3 antibodies induced by BEC2 were relatively low. Immunoglobulin genes in reactive B cells may have undergone appropriate rearrangement of variable, diversity, and junctional regions, but not somatic mutation necessary for production of high affinity antibodies. The question remains whether these B cells could undergo appropriate and selective somatic mutation, a step presumably requiring T cell help. The ability ofBEC2 to induce an IgG response suggests recruitment of T cell help. This may be analogous to a hapten-carrier protein model in which T cells recognizing peptide determinants within the carrier protein (e.g., murine-specific determinants on BEC2) provide help for the B cell population specific for hapten (e.g., the BEC2 idiotope that mimics GD3)-There appeared to be limitations to the IgG response induced by immunization with BEC2 using this route, schedule, and adjuvant. Rabbits generating IgG antibodies against GD3 did not show histological evidence of inflammation in GD13 tissues. It is possible that the affinity and titer of these anti-GD3 antibodies were too low or that immunization with BEC2 selected IgG antibodies with little or no effector functions. Although a majority ofrabbits immunized with BEC2 developed IgG against GD3, there was a subset of rabbits in which the anti-GD3 response was too weak to be scored as positive. We presume that the lack of response in this subset was related to an inability of BEC2 to stimulate the appropriate B cell clones.
It will be important to determine whether BEC2 or other anti-idiotypic MAb can elicit delayed-type hypersensitivity to carbohydrate antigens, which are classically T cell independent. However, it is not clear how carbohydrate antigens could be recognized by T cells, because T cell receptor binding appears to require presentation of antigen by MHC molecules, and binding of carbohydrates to MHC has not been demonstrated. Further studies will be necessary to test whether the immunogenicity of BEC2 can be augmented by evaluating different schedules and routes of immunization, adjuvants, and immune modulators such as interleukins and cyclophosphamide.
